Encompass Health Q2 2026 Earnings: 9.6% Revenue Growth Supports Higher Guidance

Encompass Health (NYSE: EHC) reported Q2 2026 net operating revenue of $1.597 billion, up 9.6% from $1.458 billion, while diluted EPS from continuing operations attributable to the company rose 10.7% to $1.55 from $1.40. Higher patient volumes and net patient revenue per discharge supported growth, although adjusted free cash flow declined despite higher operating cash flow. The company raised all three of its full-year guidance ranges.

Core Earnings Data

Total discharges increased 5.6%, and net patient revenue per discharge rose 3.9%, allowing Encompass Health to generate growth from both patient activity and revenue per case. Adjusted EBITDA increased at nearly the same rate as revenue, leaving the adjusted EBITDA margin approximately stable at 21.8%.

Continuing-operations income attributable to Encompass Health increased about 8.0%. Diluted EPS grew faster, partly because the diluted share count declined to 100.0 million from 102.3 million.

Adjusted EPS, adjusted EBITDA, and adjusted free cash flow are non-GAAP measures.

Operating Performance

Encompass Health recorded 68,895 discharges, compared with 65,237 a year earlier. Same-store discharges grew 2.8%, below the 5.6% increase in total discharges, indicating that capacity outside the same-store base also contributed to volume growth.

The combination of higher discharges and higher revenue per discharge explains most of the quarter’s revenue increase. The release did not provide a further breakdown of revenue by hospital, region, or payer.

Profitability, Cash Flow, and the Balance Sheet

Salaries and benefits, the company’s largest operating expense, increased to $820.3 million from $767.7 million, a slower rate than revenue growth. However, other operating expenses rose to $254.9 million from $213.8 million, while depreciation and amortization increased to $90.4 million from $79.9 million.

At June 30, 2026, cash and cash equivalents were $107.7 million, up from $72.2 million at the end of 2025. Total current and long-term debt was approximately $2.634 billion, compared with $2.491 billion at year-end. Interest expense and amortization of debt discounts and fees increased to $32.8 million from $30.4 million in the quarter.

Encompass Health repurchased $145.8 million of common stock during the first half of 2026. After approximately $188 million remained under the prior authorization at quarter-end, the board increased the aggregate repurchase authorization to $1 billion on July 23, 2026. The authorization permits repurchases but does not establish the timing or amount of future activity.

Higher Maintenance Spending Weighed on Free Cash Flow

Operating cash flow increased 4.6%, but adjusted free cash flow declined 4.8%. The principal difference was maintenance capital expenditure, which rose to $66.2 million from $45.1 million, or by about 47%. Distributions to noncontrolling interests were nearly unchanged at $40.3 million.

This divergence means earnings growth did not translate fully into higher discretionary cash generation during the quarter. It also coincided with an active development program: purchases of property, equipment, and intangible assets reached $382.7 million in the first half, up from $320.0 million a year earlier.

2026 Guidance

Encompass Health raised both ends of its full-year revenue, adjusted EBITDA, and adjusted EPS ranges. The updated outlook therefore reflects a higher expected floor as well as a higher ceiling for each metric.

Except for revenue, the company does not provide comparable GAAP guidance because it cannot reasonably predict several potential adjustments that may affect reported results.

Management’s View

CEO Mark Tarr emphasized the company’s capacity expansion. During the first half of 2026, Encompass Health opened three hospitals totaling 139 beds and added 54 beds at existing hospitals. Management expects to open five more hospitals and add more than 100 beds to existing facilities before year-end.

The expansion provides additional capacity for discharge growth, but the release did not quantify how much revenue or EBITDA the new facilities are expected to contribute in 2026.

Recent Insider Transactions

The separately provided insider dataset shows that the most recent entries were mainly director stock awards. It also records a sale by CFO Douglas Edward Coltharp; the transaction alone does not establish his view of the company’s outlook.

Risks Investors Should Watch

• Labor costs and staffing: Salaries and benefits were $820.3 million for the quarter. Difficulty attracting and retaining nurses, therapists, and other healthcare professionals could increase costs or constrain patient capacity.
• Capital spending and cash conversion: Higher maintenance spending contributed to the decline in adjusted free cash flow. Continued hospital and bed expansion may keep investment requirements elevated.
• Reimbursement and regulatory exposure: Changes to Medicare or Medicaid reimbursement, audits, claim denials, and payment delays could affect revenue and cash collections.
• Expansion execution: The company plans five additional hospital openings and more than 100 added beds before year-end. Delays, higher construction costs, or slower utilization could reduce the expected benefit.
• Debt and interest expense: Total debt increased from year-end, and quarterly interest expense rose. Additional borrowing or higher financing costs could place more pressure on cash generation.

Conclusion

Encompass Health’s Q2 2026 growth was supported by higher discharge volume and higher net patient revenue per discharge, with adjusted EBITDA broadly keeping pace with revenue. The raised full-year guidance points to greater confidence in the operating trajectory, while lower adjusted free cash flow highlights the cost of maintenance and expansion. Future results will depend on sustaining patient growth, controlling labor and other operating expenses, and converting the current development program into productive capacity.